NASDAQ · CTKB
Healthcare · Medical - Devices
$5.38
Down-$0.04 (-0.74%)
Updated Oct 7, 2026, 11:36 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTKB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
CTKB closed at $5.38 after 21 trading sessions, up 16.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $6.13 | $6.21 | $5.355 | $5.38 | 2.05M |
| Oct 5, 2026 | $5.88 | $6.105 | $5.825 | $6.09 | 1.79M |
| Oct 2, 2026 | $5.86 | $5.94 | $5.75 | $5.87 | 1.1M |
| Oct 1, 2026 | $5.96 | $5.97 | $5.7501 | $5.81 | 1.57M |
| Sep 30, 2026 | $5.76 | $5.985 | $5.67 | $5.96 | 1.32M |
| Sep 29, 2026 | $5.74 | $5.855 | $5.655 | $5.76 | 869.96K |
| Sep 28, 2026 | $5.62 | $5.78 | $5.53 | $5.74 | 1.09M |
| Sep 25, 2026 | $5.71 | $5.75 | $5.57 | $5.65 | 1.49M |
| Sep 24, 2026 | $5.64 | $5.83 | $5.48 | $5.73 | 1.6M |
| Sep 23, 2026 | $5.73 | $5.85 | $5.63 | $5.68 | 1.26M |
| Sep 22, 2026 | $5.29 | $5.84 | $5.26 | $5.71 | 3.78M |
| Sep 21, 2026 | $5.32 | $5.32 | $5.20 | $5.28 | 1.25M |
| Sep 18, 2026 | $5.09 | $5.315 | $5.09 | $5.30 | 2.09M |
| Sep 17, 2026 | $4.99 | $5.295 | $4.91 | $5.21 | 2.23M |
| Sep 16, 2026 | $4.89 | $5.005 | $4.77 | $4.93 | 1.56M |
| Sep 15, 2026 | $4.81 | $5.02 | $4.80 | $4.89 | 1.12M |
| Sep 14, 2026 | $4.62 | $4.86 | $4.57 | $4.83 | 1.17M |
| Sep 11, 2026 | $4.61 | $4.64 | $4.485 | $4.61 | 897.71K |
| Sep 10, 2026 | $4.69 | $4.70 | $4.51 | $4.53 | 2.42M |
| Sep 9, 2026 | $4.59 | $4.75 | $4.55 | $4.73 | 810.26K |
| Sep 8, 2026 | $4.64 | $4.68 | $4.54 | $4.62 | 649.72K |
The latest Smart Investors Daily articles mentioning CTKB.
Company
Market Activity
Research & News
CTKB research
Company profile and research snapshot.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Stephens & Co. | Overweight | — |
| May 12, 2026 | Morgan Stanley | Equal-Weight | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Nov 11, 2025 | Piper Sandler | Overweight | — |
| May 28, 2025 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Brown Capital Management, an investment management company, released its second-quarter 2026 investor letter for “The Brown Capital Management Small Company Fund.” The letter can be downloaded here. For the quarter ended June 30, 2026, market volatility reflected uncertainty around AI spending and Middle East tensions. The Magnificent Seven fell more than 8% in June, while […]
Yahoo · Sep 23, 2026
Industry’s First End-to-End Flow Cytometry Platform Covering Panel Design Through Data Analysis Cytek® Cloud digital ecosystem Cytek® Biosciences has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool, establishing the industry’s first end-to-end platform that integrates the entire flow cytometry workflow, from panel design to data analysis, into one system. FREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq:
ChartMill · Sep 23, 2026
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Yahoo · Sep 17, 2026
Investors need to pay close attention to CTKB stock based on the movements in the options market lately.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTKB.
